1. Pink Sheet
  2. >>R&D

Lilly Sidelined Three Drugs Due To IRA, CEO Ricks Says

 
• By Jessica Merrill

Eli Lilly & Co. CEO David Ricks highlighted how Medicare drug price negotiation policies are already impacting R&D investment during a J.P. Morgan investor call.

benched players
Lilly said it benched three pipeline drugs due to the IRA • Source: Shutterstock

A new Medicare drug price negotiation program that is being implemented by the US Centers for Medicare & Medicaid Services (CMS) as required by the Inflation Reduction Act (IRA) is already having an impact on research and development investment decisions, Eli Lilly and Company CEO David Ricks said during an investor event sponsored by J.P. Morgan on 14 June to discuss the IRA and pharmaceutical industry policy priorities.

Lilly has deprioritized three drugs as a result of the new program that will allow CMS to negotiate drug prices for certain top-selling medicines beginning in 2026, Ricks said, although he

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Pink Sheet

House Budget Bill Includes Delayed Orphan Fix, Also Risks Downstream Cell and Gene Coverage

 
• By Sarah Karlin-Smith

The first two classes of negotiated drugs under the Inflation Reduction Act would not benefit from a rare disease adjustment House Republicans included in their reconciliation package.

Trump’s Rx Pricing Order: The Best-Case And Worst-Case Scenarios

 
• By Derrick Gingery

US trade and tariff leverage might successfully push European and other countries to pay more for medicines, but if not, President Trump’s executive order includes potential US drug withdrawal and other options to entice industry to lower US prices.

International Group Aims To Shape The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.